Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b clinical trials

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

This study looks at a new drug, bomedemstat, for essential thrombocythemia (ET). It compares bomedemstat to standard treatments for people whose current medicine, hydroxyurea, isn't working well or causes too many side effects. We want to see if bomedemstat is safer and works better.